Home · Pharmacies · Strive Pharmacy
Compounding pharmacy profileStrive Pharmacy: what the records show
As of October 14, 2026, Strive Pharmacy (Gilbert, Arizona) is a 503A compounding pharmacy that lists tirzepatide/glycine/B12 and semaglutide/glycine/B12 injections and has been reported as a GLP-1 supplier to Hims & Hers. The FDA closed out its 2022 warning letter on May 13, 2026; Eli Lilly's suit against it was dismissed for lack of jurisdiction on October 8, 2025.
Strive at a glance
| Legal name | Strive Pharmacy LLC (Gilbert, AZ); Strive Pharmacy Texas LLC (Boerne, TX) |
|---|---|
| Location | 1275 E Baseline Rd #104, Gilbert, AZ 85233; seven locations claimed |
| Type | 503A compounding pharmacy |
| On FDA 503B list | No |
| Accreditations it claims | NABP accredited, PCAB (ACHC) at some locations, LegitScript — not independently verified |
| States | Says "50 States licensed in"; its provider-finder lists 42 states plus DC and Puerto Rico |
| GLP-1 products it lists | Tirzepatide/glycine/B12 and semaglutide/glycine/B12 injections |
| FDA record | Form 483, Boerne TX, Sept 8, 2023; warning letter 639220 (Aug 29, 2022) closed out May 13, 2026 |
| State board | Arizona Board of Pharmacy consent agreement Feb 7, 2024 ($1,000 fine), as reported by Sherwood News |
| Litigation | Lilly v. Strive (D. Del.) dismissed Oct 8, 2025; Strive's antitrust suit against Lilly and Novo dismissed (Reuters, Aug 6, 2026) |
Accreditation claims are the pharmacy's own; we could not check them against LegitScript's or ACHC's lookups, which were not publicly reachable. Every other row cites a source listed below.
Regulatory and legal record
An FDA inspection of Strive's Boerne, Texas pharmacy ended on September 8, 2023 with a Form 483; one observation describes a technician exposing "facial skin and hair while processing the drug product, Semaglutide/B12." The FDA closed out Strive's 2022 warning letter (639220) on May 13, 2026, stating "it appears that you have adequately addressed the violations." In Arizona, Sherwood News reported a February 7, 2024 consent agreement with a $1,000 fine; Strive described it as a documentation matter.
Eli Lilly sued Strive in Delaware over its compounded tirzepatide marketing; the court dismissed the case on October 8, 2025 for lack of personal jurisdiction. Strive's own antitrust suit against Lilly and Novo Nordisk was dismissed in August 2026, according to Reuters.
Glycine and B12 add-ins
Strive sells tirzepatide and semaglutide combined with glycine and vitamin B12. A February 2026 review in the Annals of Pharmacotherapy found "little justification for adding nutrients" to compounded GLP-1s, and the FDA said in April 2026 that semaglutide combined with B12 may still be "essentially a copy," and applied similar reasoning to tirzepatide/niacinamide in its September 2026 Empower letter. See our additives explainer.
How to verify this pharmacy yourself
Read the dispensing pharmacy's name on your vial label, then check its license with your state board of pharmacy, search the FDA outsourcing facility list if it claims 503B status, and scan the FDA's compounding inspections and actions page. Our 503A vs 503B guide explains the difference.
What the May 2026 close-out letter says
The FDA's close-out letter for warning letter 639220 is dated May 13, 2026 and was posted May 28, 2026. It is addressed to CEO Nathan Hill at Strive Pharmacy Texas LLC dba Strive Pharmacy and Vita Pharmacy, LLC dba Talon Pharmacy of Boerne. The address given is 3975 East Mesquite Street, Gilbert, AZ 85296. Matthew J. Lash, Acting Director of the FDA's Office of Compounding Quality and Compliance, signed it.
The FDA said it "has completed an evaluation of your firm's corrective actions" and that "it appears that you have adequately addressed the violations." It added that the letter "will not preclude any future regulatory action" if violations are found in a later inspection. The close-out applies only to the August 29, 2022 warning letter. It says nothing about the quality of current products, and it does not make compounded tirzepatide FDA-approved.
Is there a Strive 503B outsourcing facility now?
The FDA's registered outsourcing facility list, updated October 29, 2026, includes Strive Outsourcing LLC, Alachua, Florida. Its initial registration date is October 23, 2026, and it is marked "Not yet inspected." We have not confirmed whether it belongs to the same company as Strive Pharmacy in Gilbert. The Strive pharmacies covered on this page remain 503A.
A 503B registration would not, on its own, let a facility make tirzepatide from bulk ingredient. The FDA says tirzepatide is on neither the 503B bulks list nor the drug shortage list. On April 30, 2026 the FDA proposed keeping tirzepatide, semaglutide and liraglutide off the bulks list. Comments closed July 30, 2026, and no final decision had been published as of November 4, 2026. See what the bulks-list proposal means.
Strive's legal and regulatory timeline
| Date | Event |
|---|---|
| August 29, 2022 | FDA warning letter 639220 to Strive Pharmacy Texas (Boerne) |
| September 8, 2023 | FDA Form 483 after inspection of the Boerne pharmacy (semaglutide/B12 named in one observation) |
| February 7, 2024 | Arizona Board of Pharmacy consent agreement, $1,000 fine (as reported by Sherwood News) |
| About April 1, 2025 | Eli Lilly sues Strive in Delaware federal court over compounded tirzepatide |
| October 8, 2025 | Lilly's Delaware case dismissed for lack of personal jurisdiction |
| January 2026 | Strive's antitrust suit against Lilly and Novo Nordisk (W.D. Tex.) reported |
| May 13, 2026 | FDA closes out warning letter 639220 |
| August 6, 2026 | Reuters reports Strive's antitrust suit dismissed |
| October 23, 2026 | Strive Outsourcing LLC (Alachua, FL) first registered as a 503B facility; link to Strive Pharmacy not confirmed |
Strive's main tirzepatide product contains glycine and B12. In its September 18, 2026 warning letter to Empower, the FDA said tirzepatide/niacinamide and semaglutide/B12 products "appear to be essentially copies" of approved drugs. That letter did not name Strive, but it shows how the FDA now treats additive formulations. If your prescription is for tirzepatide/glycine/B12, ask your prescriber to state the clinical reason for the additive.
Questions to ask a program that fills through Strive
- Is my prescription for tirzepatide alone or for tirzepatide/glycine/B12, and what is the concentration?
- What clinical reason has the prescriber recorded for the additive formulation?
- Which Strive location will fill it: Gilbert, Boerne or another site? Each has its own license and FDA history.
- Does Strive hold a license in my state? Its site says 50 states, but its provider finder lists 42 states plus DC and Puerto Rico.
Write down the answers, and compare them with the first vial label you receive.
More questions
Who signed Strive's FDA close-out letter?
Matthew J. Lash, Acting Director of the FDA's Office of Compounding Quality and Compliance. The letter is dated May 13, 2026.
Is Strive Outsourcing LLC the same company as Strive Pharmacy?
We have not confirmed it. The FDA lists Strive Outsourcing LLC in Alachua, Florida as a 503B facility registered October 23, 2026 and not yet inspected.
Does the close-out letter cover every FDA concern about Strive?
No. It refers only to warning letter 639220 from August 29, 2022, and it says it does not prevent future regulatory action.
Further sources
- FDA close-out letter, Strive Pharmacy Texas LLC dba Strive Pharmacy, MARCS-CMS 639220 (May 13, 2026)
- FDA: Registered Outsourcing Facilities (list updated October 29, 2026)
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated April 1, 2026)
- FDA warning letter 738238, Empower Clinic Services LLC dba Empower Pharmacy (September 18, 2026)
Frequently asked questions
Does Strive Pharmacy supply Hims & Hers?
Sherwood News reported in February 2026 that Strive provides GLP-1s to several telehealth companies, including Hims & Hers.
Is Strive Pharmacy 503A or 503B?
503A. Strive describes itself as "a patient-first 503A compounding pharmacy," and it is not on the FDA's outsourcing facility list.
Was Strive sued by Eli Lilly?
Yes; the Delaware case was dismissed on October 8, 2025 for lack of personal jurisdiction, not on the merits.
Sources
Other pharmacy profiles: Empower Pharmacy · Hallandale Pharmacy · MediVera Compounding Pharmacy · Red Rock Pharmacy · Absolute Pharmacy · all pharmacies
Informational only. A pharmacy profile is not an endorsement. Compounded drugs are not FDA-approved.